S P Curtis

Summary

Affiliation: Merck Research Laboratories
Country: USA

Publications

  1. pmc A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273]
    Eduardo Collantes
    Hospital Reina Sofia, Cordoba, Spain
    BMC Fam Pract 3:10. 2002
  2. pmc Single dose methodology to assess the influence of an alpha1-adrenoceptor antagonist on uroflowmetric parameters in patients with benign prostatic hyperplasia
    S P Curtis
    Division of Clinical Pharmacology, Merck and Co, Rahway, NJ 07065, USA
    Br J Clin Pharmacol 49:269-73. 2000
  3. pmc Etoricoxib in the treatment of osteoarthritis over 52-weeks: a double-blind, active-comparator controlled trial [NCT00242489]
    Sean P Curtis
    Merck and Co, Inc, Rahway, NJ, USA
    BMC Musculoskelet Disord 6:58. 2005
  4. ncbi request reprint Renal effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs in controlled clinical trials
    Sean P Curtis
    Department of Clinical Research, Merck Research Laboratories, Rahway, New Jersey 07065, USA
    Clin Ther 26:70-83. 2004
  5. ncbi request reprint Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison
    Christopher P Cannon
    Thrombolysis in Myocardial Infarction TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Lancet 368:1771-81. 2006
  6. ncbi request reprint The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis
    Dena R Ramey
    Epidemiology, Merck Research Laboratories, West Point, PA 19486, USA
    Curr Med Res Opin 21:715-22. 2005
  7. pmc Evaluation of the efficacy and safety of etoricoxib in the treatment of hemophilic arthropathy
    Christos Tsoukas
    McGill University Health Centre, Montreal General Hospital, 1650 Cedar Ave, Rm A5 140, Montreal, QC H3G 1A4, Canada
    Blood 107:1785-90. 2006
  8. ncbi request reprint Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis
    Christopher P Cannon
    The TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Am Heart J 152:237-45. 2006
  9. ncbi request reprint Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: results of the Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) trial
    Herbert S B Baraf
    Center for Rheumatology and Bone Research, Wheaton, Maryland 20902, USA
    J Rheumatol 34:408-20. 2007
  10. ncbi request reprint Pooled analysis of thrombotic cardiovascular events in clinical trials of the COX-2 selective Inhibitor etoricoxib
    Sean P Curtis
    Merck Research Laboratories, Rahway, NJ 07065, USA
    Curr Med Res Opin 22:2365-74. 2006

Collaborators

Detail Information

Publications13

  1. pmc A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273]
    Eduardo Collantes
    Hospital Reina Sofia, Cordoba, Spain
    BMC Fam Pract 3:10. 2002
    ..Etoricoxib is a highly selective COX-2 inhibitor which was evaluated for the treatment of rheumatoid arthritis (RA)...
  2. pmc Single dose methodology to assess the influence of an alpha1-adrenoceptor antagonist on uroflowmetric parameters in patients with benign prostatic hyperplasia
    S P Curtis
    Division of Clinical Pharmacology, Merck and Co, Rahway, NJ 07065, USA
    Br J Clin Pharmacol 49:269-73. 2000
    ..This methodology could then be applied to screening new drugs to treat BPH...
  3. pmc Etoricoxib in the treatment of osteoarthritis over 52-weeks: a double-blind, active-comparator controlled trial [NCT00242489]
    Sean P Curtis
    Merck and Co, Inc, Rahway, NJ, USA
    BMC Musculoskelet Disord 6:58. 2005
    ..The aim of this study was to evaluate the long-term efficacy and tolerability of etoricoxib, a COX-2 selective inhibitor, in osteoarthritis (OA) patients...
  4. ncbi request reprint Renal effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs in controlled clinical trials
    Sean P Curtis
    Department of Clinical Research, Merck Research Laboratories, Rahway, New Jersey 07065, USA
    Clin Ther 26:70-83. 2004
    ....
  5. ncbi request reprint Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison
    Christopher P Cannon
    Thrombolysis in Myocardial Infarction TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Lancet 368:1771-81. 2006
    ..The MEDAL programme was designed to provide a precise estimate of thrombotic cardiovascular events with the COX-2 selective inhibitor etoricoxib versus the traditional NSAID diclofenac...
  6. ncbi request reprint The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis
    Dena R Ramey
    Epidemiology, Merck Research Laboratories, West Point, PA 19486, USA
    Curr Med Res Opin 21:715-22. 2005
    ....
  7. pmc Evaluation of the efficacy and safety of etoricoxib in the treatment of hemophilic arthropathy
    Christos Tsoukas
    McGill University Health Centre, Montreal General Hospital, 1650 Cedar Ave, Rm A5 140, Montreal, QC H3G 1A4, Canada
    Blood 107:1785-90. 2006
    ..6%) and during part 2 between etoricoxib (77.0%) and rofecoxib (78.9%). We conclude that etoricoxib provided superior efficacy versus placebo for the treatment of hemophilic arthropathy and was generally safe and well tolerated...
  8. ncbi request reprint Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis
    Christopher P Cannon
    The TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Am Heart J 152:237-45. 2006
    ..The MEDAL program will help to better define the risk-to-benefit ratio of 2 NSAIDs, that differ in their selectivity for COX-2, notably diclofenac and etoricoxib...
  9. ncbi request reprint Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: results of the Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) trial
    Herbert S B Baraf
    Center for Rheumatology and Bone Research, Wheaton, Maryland 20902, USA
    J Rheumatol 34:408-20. 2007
    ..To compare the gastrointestinal (GI) tolerability, safety, and efficacy of etoricoxib and diclofenac in patients with osteoarthritis (OA)...
  10. ncbi request reprint Pooled analysis of thrombotic cardiovascular events in clinical trials of the COX-2 selective Inhibitor etoricoxib
    Sean P Curtis
    Merck Research Laboratories, Rahway, NJ 07065, USA
    Curr Med Res Opin 22:2365-74. 2006
    ....
  11. ncbi request reprint Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison
    Loren Laine
    Division of Gastrointestinal and Liver Diseases, Department of Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA 90033, USA
    Lancet 369:465-73. 2007
    ..Our aim was to assess the effects of these drugs on gastrointestinal outcomes in a population that includes patients taking gastrointestinal protective therapy...
  12. ncbi request reprint The effects of modifying in vivo cytochrome P450 3A (CYP3A) activity on etoricoxib pharmacokinetics and of etoricoxib administration on CYP3A activity
    Nancy G B Agrawal
    Merck Research Laboratories, West Point, PA 19486, USA
    J Clin Pharmacol 44:1125-31. 2004
    ..Etoricoxib had no effect on hepatic CYP3A activity, as assessed by the erythromycin breath test...
  13. ncbi request reprint Etoricoxib versus naproxen in patients with rheumatoid arthritis: a prospective, randomized, comparator-controlled 121-week trial
    Alan Matsumoto
    Arthritis and Rheumatism Associates, Wheaton, MD, USA
    Curr Med Res Opin 23:2259-68. 2007
    ..The present two-part extension of that study was performed to monitor tolerability and examine long-term efficacy of etoricoxib 90 mg or 120 mg compared with naproxen...